We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$466M
AUM Growth
-$255M
Cap. Flow
-$296M
Cap. Flow %
-63.44%
Top 10 Hldgs %
56.9%
Holding
92
New
18
Increased
13
Reduced
21
Closed
28

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.79M
2
FIVN icon
FIVE9
FIVN
+$5.96M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.67M
4
GNRC icon
Generac Holdings
GNRC
+$5.66M
5
ATXS
Astria Therapeutics
ATXS
+$4.84M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$41.8M
2
AZN icon
AstraZeneca
AZN
+$31.2M
3
SNY icon
Sanofi
SNY
+$28.8M
4
NVO
Novo Nordisk
NVO
+$26.4M
5
MRK icon
Merck
MRK
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 60.42%
2 Technology 2.22%
3 Industrials 2%
4 Communication Services 0.09%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
CALL
Invesco QQQ Trust
QQQ
$453B
$61.5M 13.2%
+231,000
New +$63.9M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$453B
$55.9M 12%
210,000
-115,500
-35% -$31.9M
AZN icon
3
AstraZeneca
AZN
$263B
$27.1M 5.82%
200,030
-248,500
-55% -$31.2M
SNY icon
4
Sanofi
SNY
$103B
$27.1M 5.82%
559,515
-655,000
-54% -$28.8M
TEVA icon
5
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$20.3M 4.35%
2,222,300
+12,300
+0.6% +$107K
JNJ icon
6
Johnson & Johnson
JNJ
$618B
$19.4M 4.16%
109,831
-106,320
-49% -$18.4M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.69B
$18.1M 3.88%
710,561
-112,135
-14% -$2.62M
MRK icon
8
Merck
MRK
$322B
$13.4M 2.87%
120,600
-246,400
-67% -$25.2M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.84B
$12.3M 2.64%
671,644
+45,092
+7% +$795K
ALBO
10
DELISTED
Albireo Pharma Inc
ALBO
$10M 2.15%
463,828
+104,828
+29% +$2.22M
ABBV icon
11
AbbVie
ABBV
$443B
$9.7M 2.08%
60,000
-102,285
-63% -$15.7M
NVO
12
Novo Nordisk
NVO
$208B
$9.68M 2.08%
143,080
-449,800
-76% -$26.4M
LLY icon
13
Eli Lilly
LLY
$1.02T
$9.4M 2.02%
25,690
-117,860
-82% -$41.8M
KZR
14
DELISTED
Kezar Life Sciences
KZR
$9.19M 1.97%
130,518
+5,937
+5% +$440K
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.45B
$8.51M 1.83%
183,696
+10,000
+6% +$393K
SWTX
16
DELISTED
SpringWorks Therapeutics
SWTX
$8.24M 1.77%
316,625
+15,000
+5% +$370K
KROS icon
17
Keros Therapeutics
KROS
$199M
$7.62M 1.64%
158,757
-48,062
-23% -$2.25M
ACLX
18
DELISTED
Arcellx
ACLX
$7.36M 1.58%
237,488
-96,592
-29% -$2.22M
ATXS
19
DELISTED
Astria Therapeutics
ATXS
$6.99M 1.5%
+469,340
New +$4.84M
TSEM icon
20
PUT
Tower Semiconductor
TSEM
$24.8B
$6.98M 1.5%
+161,600
New +$7.02M
PNT
21
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$6.94M 1.49%
952,642
-100,200
-10% -$744K
KURA icon
22
Kura Oncology
KURA
$800M
$6.93M 1.49%
558,287
-231,665
-29% -$3.37M
IMTX icon
23
Immatics
IMTX
$1.18B
$6.8M 1.46%
780,852
-14,554
-2% -$151K
CINC
24
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$6.51M 1.4%
529,640
+410,690
+345% +$9.79M
FIVN icon
25
FIVE9
FIVN
$2.11B
$6.45M 1.38%
+95,000
New +$5.96M
1
2 3 4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2022 Portfolio in Review

As of Q4 2022, Sphera Funds Management held 92 positions worth $466M, down 35% from $720M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sphera Funds Management withdrew a net $296M in Q4 2022, closing 28 positions and reducing 21 holdings. Its most notable exit was Palo Alto Networks, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 66% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in FIVE9 worth $6.45M.

  • Sphera Funds Management's largest Q4 2022 buy was FIVE9: 95,000 shares worth $6.45M.
  • Sphera Funds Management added most to CinCor Pharma, Inc. Common Stock in Q4 2022, an estimated $9.79M increase.
  • Sphera Funds Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $41.8M.
  • Sphera Funds Management fully exited Palo Alto Networks in Q4 2022, selling an estimated $10.3M.
  • Sphera Funds Management's ten largest holdings make up 57% of its $466M portfolio in Q4 2022.
  • Sphera Funds Management opened 18 new positions and closed 28 in Q4 2022.
  • Sphera Funds Management's portfolio value fell 35% quarter-over-quarter to $466M.

Based on Sphera Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.